Amylin Pharmaceuticals

Top Story

Amylin acquisition marks new chapter in Bristol-Myers Squibb, AstraZeneca diabetes alliance

Bristol-Myers Squibb’s (NYSE:BMY) $7 billion acquisition of Amylin Phramaceuticals (NASDAQGS:AMLN) is one of the largest diabetes deals for the year to date. Given Bristol-Myers Squibb’s and AstraZeneca’s (NYSE:AZN) five-year-old diabetes drug development alliance, the latest deal stands to position them in stronger competition with Sanofi, Novo Nordisk and Merck. As part of the deal, AstraZeneca […]